Fig. 1
From: Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia
In vitro characterization of latozinemab. A Binding curve of sortilin-expressing HEK293T cells by latozinemab. n = 4 technical replicates for latozinemab, n = 5 technical replicates for isotype control. B Percentage of dose-dependent blocking of human PGRN binding to sortilin by latozinemab. n = 3 technical replicates for latozinemab, n = 2 technical replicates for isotype control. C Dose-dependent decrease in surface sortilin expression on U251 cells. n = 3 technical replicates for latozinemab, n = 2 technical replicates for isotype control. D Extracellular PGRN is increased relative to baseline (dashed line) in the presence of latozinemab. n = 3 technical replicates for latozinemab, n = 2 technical replicates for isotype control. All data represent the mean ± SD. 2–5 technical replicates shown for each experiment, each experiment was repeated N > 3, representative data are shown. PE, phycoerythrin; PGRN, progranulin